Chapter 46: Genetic Testing for Hereditary Breast and Ovarian Cancer

Welcome to Last Minute Lecture.

This free chapter overview is designed to help students review and understand key concepts.

These summaries supplement not replaced the original textbook and may not be redistributed or resold.

For complete coverage, always consult the official text.

Imagine a young woman sitting in your exam room.

She is, by all accounts, perfectly healthy.

She exercises, she eats well, she feels totally fine.

Right.

But based on just a few invisible lines of code in her DNA, she's just been told she possesses like up to a 90 % chance of developing breast cancer.

It's a staggering number.

Yeah, it is.

So today we are talking about treating a tumor that's already there.

We are talking about hunting down the genetic ghosts that predict a cancer before it ever strikes.

Welcome to a very special study session, Deep Dive.

If you're a nursing or advanced practice student listening to this, you are in exactly the right place.

Absolutely, because this is a profound shift in how we think about medicine.

As a future clinician, you're going to be on the absolute front lines of this.

You won't just be reacting to illness anymore.

You will be predicting it.

Which is huge.

Exactly.

So our goal today is to help you build a really solid mental framework for navigating hereditary breast and ovarian cancer.

We're drawing the core of our discussion directly from chapter 46 of Advanced Health Assessment of Women.

That way, when you're actually sitting in that exam room, the right questions, the right clinical logic and the right next steps just come to you naturally.

Okay, let's unpack this because to outsmart cancer, you really have to know what you're up against.

And before we can assess the risk of the individual patient sitting on the exam table, we have to understand the baseline risk of the general population, right?

Like if we don't know what normal looks like, how can we possibly spot the outliers?

You absolutely need that baseline.

And the text lays out some pretty stark statistics to ground us.

Let's look at breast cancer first.

It remains the most frequently diagnosed cancer in U .S.

women.

Still number one.

Yeah, still number one.

We're looking at roughly 290 ,000 new cases and over 43 ,000 deaths annually.

So for the average woman walking down the street, her baseline lifetime risk of developing breast cancer is 12 .5%.

So that's what, a one in eight chance?

Exactly, one in eight.

Just by virtue of being a woman?

I mean, that is a massive baseline to start from.

It really is.

Now, ovarian cancer, that's a different story.

It's the ninth most common cancer with nearly 20 ,000 cases annually.

But here is the critical, honestly terrifying part.

It ranks fifth in cancer deaths.

Wow, fifth in deaths, but only ninth in cases.

Right, because the average lifetime risk is only 1 .5 % or about one in 78.

So it's rare, but it is incredibly deadly because frankly, we just don't have good early screening for it.

Makes sense.

Now, you have to remember the vast majority of both breast and ovarian cancers are sporadic.

They just happen by chance due to, you know, acquired cellular damage over a long lifetime.

Right, but sporadic means it wasn't inherited.

We are here today to talk about the ones that are inherited, the ones passed down from parent to child.

Precisely.

About five to 10 % of breast cancers and a full 15 % of ovarian cancers are hereditary.

They're caused by a single gene germline mutation

and the absolute heavy hitters in this category.

The names you will see constantly in practice are the BRCA1 and BRCA2 genes.

Wait, I've always found the phrasing around this a little confusing.

We constantly talk about like getting the BRCA gene, like it's a disease itself, but don't we all have BRCA genes?

Yes, that is a fantastic point of clarification and honestly, a super common misconception.

Every single human being has BRCA1 and BRCA2 genes.

They're what we call tumor suppressor genes.

Okay.

Their normal everyday job is to act as the body's mechanics.

They produce proteins that constantly scan our DNA for damage and repair it.

You know, I always like to think of these tumor suppressor genes like safety inspectors in a factory.

Oh, I like that.

Right, so normally you have two inspectors on the floor, one you inherited from your mom, one from your dad.

If you inherit one mutated copy, so like a broken gene, you've only got one working inspector on the floor.

And the factory still runs.

Exactly.

The factory still runs.

But if that second inspector calls in sick, or if that second gene gets damaged by radiation or just, you know, a random copying error over time, there's nobody left to fix the machinery.

Mistakes happen fast.

Cells start dividing out of control.

And that is cancer.

That is the exact mechanism.

You lose that primary DNA repair system.

These mutations are inherited in an autosomal dominant pattern, which means a child has a 50 % chance of inheriting the broken inspector from a carrier parent.

Coin flip.

Literally a coin flip.

In the general population, the prevalence of carrying a mutated BRCA gene is somewhere between one in 300 to one in 800.

But the text notes that in certain groups, like individuals of Ashkenazi Jewish descent, that prevalence jumps astronomically to one in 40.

Why is that?

It's due to something called a founder effect.

So centuries ago, a small group of individuals, some of whom just happened to carry this specific genetic mutation, became isolated due to geography or cultural practices.

Okay.

So a smaller gene pool.

Exactly.

As that specific population grew and reproduced within its own community, that specific genetic variant was amplified across generations.

It's a crucial, crucial piece of demographic data to gather during your history taking.

Okay.

So we know how they work and who might be at higher risk.

But clinically, do we treat a BRCA1 mutation exactly the same as a BRCA2 mutation?

No, not at all.

And this is where your clinical interpretation as a provider really matters.

The phenotypes, how the genes actually express themselves in the patient, they're distinct.

With a BRCA1 mutation, you are generally looking at a much younger onset of breast cancer.

And crucially, the histology is different.

They are highly likely to be triple negative breast cancers.

Triple negative.

So meaning the tumor cells test negative for estrogen receptors, negative for progesterone receptors, and they don't overexpress the HER2 protein.

Right.

And I know from clinical rotations that triple negative is notoriously hard to treat because you basically can't use targeted hormone therapies to starve the tumor.

Exactly.

You can't just block estrogen to stop it.

You are left relying primarily on blunt force chemotherapy.

Now contrast that with BRCA2.

The age of onset for breast cancer in a BRCA2 carrier is actually closer to that of a non -inherited sporadic cancer.

Oh, so it hits a bit later.

Yes, generally.

And the tumors are also more likely to be estrogen and progesterone receptor positive, which gives us way more treatment targets.

Okay.

That's a big difference.

And what about the other cancer risks?

Is it just breast and ovarian for both?

There are differences there too.

For BRCA1, the ovarian cancer onset is usually earlier.

For BRCA2, the ovarian cancer risk hits about 8 to 10 years later.

But BRCA2 brings a whole host of other unique risks.

Like what?

Well, there is a much higher rate of male breast cancer, for starters, as well as an increased risk for deadly melanomas and pancreatic cancer.

Oh, wow.

Okay.

So if you're taking notes right now, BRCA1 is the early striker, the triple negative threat.

BRCA2 is the later onset hormone positive threat that also brings males, skin, and pancreas into the crosshairs.

That's a perfect summary.

So how do we actually spot these genetic ghosts in the exam room?

Because we obviously don't just run a $3 ,000 genetic panel on every single person who walks through the door.

No, insurance would never allow that.

You start with the most powerful, cost -effective tool in all of medicine, a meticulous family history.

But, and I want to stress this, not just a casual, hey, does cancer run in your family kind of question.

Right.

You have to dig deep.

You do.

You need to construct a minimum three -generation pedigree of both the maternal and paternal lines.

And you really need to map this out visually, right?

I've seen the diagrams in the textbook where you use squares to represent males circles for females.

And if, say, a woman had ovarian cancer at age 50, you draw her circle shade in a quadrant of it and write 050 right next to it, it creates this immediate visual heat map of where the genetic fire is basically burning in the family tree.

It does.

And you're looking for patterns on that map.

Are there multiple generations affected?

Is there bilateral disease, like cancer in both breaths?

Are we seeing breast cancer in male relatives?

But here is the challenge with that.

What's that?

Visual heat maps are subjective.

As a clinician, you need a concrete mathematical way to quantify that risk to justify referring this patient to a genetic counselor.

Right.

Because, like we said, insurance isn't going to pay for testing just because I drew a scary -looking family tree on a clipboard.

Exactly.

I saw the text highlights the Ontario Family History Assessment Tool.

How does the math on that actually work in practice?

So the Ontario Tool, which is backed by the U .S.

Preventive Services Task Force,

assigns specific point values to different relatives based on their genetic distance to the patient and the severity of their disease.

Okay.

So explain the genetic distance part.

Why does the math change based on exactly who has the cancer?

Because you share 50 % of your DNA with your first -degree relatives, so your parents, your siblings, your children.

So if your mother had breast or ovarian cancer, the Ontario Tool assigns a massive 10 points to your score right out of the gate.

Got it.

But you only share 25 % of your DNA with a second -degree relative, like an aunt or a grandmother.

So a second -degree relative with cancer might only add five points.

And the age of onset changes the math too, doesn't it?

Significantly.

Because remember, hereditary cancers tend to strike earlier than sporadic ones.

If a relative had breast cancer onset in their 20s, that adds six extra points.

But if the onset was in their 40s, it only adds two points.

Let's do a quick clinical scenario just to see it in action.

Sure.

Imagine your patient's mother had breast cancer at age 45, and her sister had it at age 38.

Let's tally that up.

Okay, let's do it.

So mother with cancer is 10 points, sister is seven points.

Mother's onset in her 40s adds two points.

Sister's onset in her 30s adds four points.

So that is a total of 23 points.

Exactly.

You nailed the math.

And a total family score of 10 or greater is the threshold that triggers an immediate referral for genetic testing.

10 points is the cutoff, and she had 23.

Right.

Just hitting that 10 -point mark corresponds to a doubling of the patient's lifetime risk for breast cancer, pushing them from that 12 .5 % baseline we talked about up to about 22%.

Okay, so she hits 23 points.

We know she absolutely needs testing.

But I'm looking at her sitting on the exam table right now.

Do I just swab her cheek right then and there?

Actually, no.

And this is a massive clinical pearl for the students listening.

Always try to test the family member who was already affected with cancer first.

We call them the pro band.

Wait, I'm confused.

My patient is the healthy woman sitting in front of me.

Why would I send her away and ask her to get her sick sister tested instead?

That seems like a logistical nightmare.

It can be a huge logistical headache, but medically it is essential.

Think of it like this.

If you test the healthy woman and she is negative,

you don't actually know if she's safe.

Because her family might carry a rare mutation that your specific test just didn't look for.

But if you test the sister who already has the cancer and you find a broken BRCA1 gene, you have found the exact smoking gun responsible for the family's disease.

Oh, I see.

Yeah, once you know exactly what the smoking gun looks like, then you test your healthy patient to see if she inherited that specific weapon.

That makes total sense when you put it like that.

But what if the affected family member has passed away or is estranged and just refuses to be tested?

In the real world, that happens constantly.

Families are complicated.

In that case, you can refer the unaffected woman for testing based on her high Ontario score or by running her data through validated risk models like BCAPRO, Bodecia, or Tyroacusic.

And seriously, underline this in your notes.

Absolutely do not use the Gale model to assess hereditary risk.

Why not?

I hear the Gale model mentioned all the time in women's health.

You do.

But the Gale model is designed to calculate the risk of sporadic breast cancer.

It looks at things like the age of a woman's first period or how many breast biopsies she has had.

Oh, so it's not looking for genetics.

Right.

It severely underestimates the risk driven by highly penetrant germline mutations.

It is completely the wrong tool for this specific job.

Understood.

No Gale model for genetic ghosts.

So we've identified the right candidate.

The clinical step before we ever draw blood is pre -test counseling, right?

We don't just hand them a lab form to sign.

Never.

Pre -test counseling is mandatory, ideally done by a certified genetic counselor.

You are helping the patient formulate a psychological plan for how they will handle the results, whatever they are.

And practically speaking, you have to talk about insurance and the Genetic Information Nondiscrimination Act, or Giana.

This is a huge fear for patients.

I hear this a lot.

They think, if I take this test and it's positive, my health insurance is going to drop me because I'm basically a walking pre -existing condition.

Does Giana completely protect them?

It protects them from health insurance discrimination and employment discrimination.

So a health insurer cannot deny coverage or raise premiums based on a genetic test.

But here is the glaring loophole you must warn your patients about.

Giana does not protect against discrimination from life insurance, long -term care insurance, or disability insurance.

Oh, wow.

So a life insurance company absolutely can use this test to deny a 30 -year -old mother a policy.

Yes, they absolutely can.

And patients need to weigh that reality and maybe get their policies in place before they consent to lab work.

That's a huge real -world consideration.

So what does this all mean when the results actually come back?

So they consent, the lab runs the panel, and the report comes back.

How do we interpret the results?

Because I imagine it's not just a simple positive or negative.

Far from it.

There are four distinct outcomes you have to navigate as a clinician.

Outcome one is a deleterious mutation.

This is a clear definitive positive.

The broken inspector.

Exactly.

It means the safety inspector is broken.

Their lifetime risk for breast cancer skyrockets to between 41 % and 90%.

And their ovarian risk jumps to between 8 % and 62%.

It also means every first -degree relative they have now has a coin flip, 50 % chance of carrying the same mutation.

OK, that's the heavy one.

Outcome two is the true negative.

Now, this sounds like the best -case scenario.

It is biologically the best case.

A true negative means we previously found the smoking gun mutation in the sick family member, and this specific patient did not inherit it.

So she dodged the bullet.

She did.

Her risk plummets right back down to the 12 .5 % population baseline.

But what's fascinating here is the psychological fallout.

How so?

You'd think she would just be, like, thrown a party.

You really would think that.

But the text explicitly notes that a true negative can lead to intense survivor guilt.

Oh, wow.

I wouldn't have even thought of that.

Yeah.

Imagine being the only sister out of four who dodged the mutation, watching the women you love undergo mastectomies and chemotherapy, while you are completely fine.

The psychological burden of surviving your own family's genetic curse requires serious emotional support.

That really highlights why we treat the whole patient, not just the lab slip.

OK, what is outcome three?

The uninformative negative.

This happens when we couldn't test the sick family member first.

We test our healthy patient, and she is negative.

But we don't know if her family's history of cancer is caused by a completely different undiscovered gene, or if it was just a horrible streak of sporadic bad luck.

So you're left in the dark, basically.

Basically.

Because it's uninformative, we still have to manage her as a high -risk patient based on her family tree, despite the negative blood test.

And the final outcome, which just sounds incredibly frustrating, the variant of uncertain significance, or VUS.

Yeah, this happens in about 3 % to 5 % of tests.

The lab reads the DNA and finds a spelling error in the code.

But when they check the global databases, there isn't enough data yet to know if this specific spelling error actually causes cancer, or if it's just a harmless cork like having a freckle on your arm.

You're telling me we do this highly advanced emotionally taxing test, and the lab basically comes back and says, we don't know.

What do you even tell the patient in that room?

You tell them that the vast majority of VUS results are eventually reclassified as harmless as more global research comes in.

You do not recommend radical surgeries based on a VUS.

You manage them based on their family history until the science catches up.

OK, so history led to testing.

Testing led to interpretation.

Now, interpretation mandates action.

Let's walk through the clinical protocol for an unaffected woman who receives that definitive, positive, deleterious mutation result.

How do we manage the breasts?

We start surveillance aggressively, and we start early.

Breast awareness at age 18.

By age 25, she is getting clinical breast exams every 6 to 12 months, and she begins an annual breast MRI with contrast.

From age 30 to 75, we add an annual mammogram, ideally a 3D tomosynthesis alongside the MRI.

Wait, why are we doing an expensive MRI at age 25?

Why not just start with a standard mammogram?

Because young women have very dense breast tissue.

On a mammogram, dense tissue shows up white.

Tumors also show up white.

Ah, so it's like trying to find a snowball in a blizzard.

Exactly.

That's a perfect way to picture it.

An MRI uses magnetic fields and contrast dye to bypass the density issue, making it highly sensitive for young carriers.

But all of this imaging is basically just waiting for the cancer to show up.

How do we actively prevent it?

The most effective prevention is surgical, a prophylactic bilateral mastectomy.

Removing the healthy breast tissue reduces the risk of developing breast cancer by 90%.

Alternatively, we can consider chemoprevention medications like tamoxifen or roloxafine.

But hold on, we talked earlier about how BRCA1 mutations usually cause triple negative breast cancer, meaning no estrogen receptors.

Drugs like tamoxifen work by blocking estrogen.

So do they even work for BRCA1 carriers?

That is brilliant clinical reasoning.

The data shows tamoxifen is highly effective at preventing cancer in BRCA2 carriers, who typically get estrogen -positive tumors.

For BRCA1 carriers, the preventive benefit of tamoxifen is far less clear, though it might offer some protection against cancers in the opposite breast if they've already had one tumor.

Okay, so we can monitor or remove the breasts because they are on the outside of the body.

But what happens when the mucation targets an organ completely hidden from view, like the ovaries, where early detection is nearly impossible?

This is the toughest part.

Because we cannot reliably screen for early -stage ovarian cancer, the gold standard recommendation is a risk -reducing salpingo -uferectomy, or an RRSO.

This means surgically removing both the ovaries and the fallopian tubes between ages 35 and 40, ideally after the woman has finished having children.

Hold on, if the gold is preventing ovarian cancer, why on earth are we surgically removing her fallopian tubes?

Doesn't that just add unnecessary surgical complexity?

It sounds counterintuitive, I know, but recent pathology has completely rewritten our understanding of this disease.

We now know that a massive percentage of what we used to call ovarian cancers actually begin as microscopic malignant cells in the fimbriae.

The fimbriae, so the very tips of the fallopian tubes that brush against the ovary during ovulation.

Exactly, so removing the tubes is paramount.

An RRSO reduces the risk of gynecologic cancer by a staggering 80 to 85 percent.

That is a massive biological revelation, but we have to acknowledge the human cost here.

We are talking about surgically inducing menopause in a 35 -year -old woman.

Yes, we are, and the sudden drop in hormones causes severe vasomotor symptoms, hot flashes, it accelerates bone loss, and increases cardiovascular risk.

It is a buccal trade -off for survival.

And interestingly, if she's premenopausal at the time of the surgery, removing those estrogen -producing ovaries also slashes her breast cancer risk by 50 percent.

What if she says no?

What if she wants to have another child at 38?

If she delays surgery, you can offer a transvaginal ultrasound and checking the CA125 tumor marker in her blood every six months.

But you must look her in the eye and be absolutely clear this is not an effective screen.

You have to be blunt about it.

You have to be.

It does not reliably catch early ovarian cancer.

It is just the best we can do when surgery isn't an option.

What about lifestyle interventions?

I saw the text mentions oral contraceptives in box 46 .2.

This is a really fascinating clinical paradox.

Taking oral contraceptives for several years reduces the risk of ovarian cancer by 50 percent in BRCA carriers because it stops the constant trauma of ovulation.

Okay, that sounds great.

It is, but however, using those same hormones for more than five years might slightly increase her risk of breast cancer.

It is a delicate balancing act you have to manage with a patient.

And everything we just discussed was for the unaffected woman.

If the patient who tests positive already has breast cancer, the text notes her risk for an ipsilateral recurrence.

So cancer coming back in the same breast or a completely new contralateral cancer in the opposite breast is so high that a bilateral mastectomy is heavily favored over just doing a lumpectomy.

Right.

The approach is much more aggressive.

Okay, so BRCA is the big bad wolf here.

But what if that pedigree screams hereditary cancer, but the BRCA test comes back completely normal?

That's when you have to recognize the BRCA isn't the only genetic ghost.

There are other highly penetrant syndromes you need to be aware of.

For instance, life from any syndrome, which is caused by a mutation in the TP53 gene.

TP53 is basically the master watchman of the entire genome, right?

Exactly.

When TP53 breaks, it's not just breast or ovarian cancer.

You see devastatingly young onset cancers across multiple systems, brain tumors, childhood sarcomas, leukemias.

Then there's Lynch syndrome, which primarily drives colon and endometrial cancer, but also carries significant ovarian cancer risks.

And PTN mutations causing Cowden syndrome, which links thyroid, breast, and uterine cancers.

Here's where it gets really interesting.

Because modern technology is completely changing the game.

We don't have to guess which specific syndrome it is and test them one by one anymore.

We have next generation gene sequencing.

We can run multi -gene panels that test 40 different cancer genes all at once.

It is an incredible technological leap.

But it brings a massive clinical gray area.

How so?

While we have the technology to test 40 genes at once, the medical community completely lacks clear management guidelines for many of the lower penetrant genes on those panels.

We might find a mutation and know it increases her risk slightly, but we don't have the hard data to say you need your ovaries removed at 40.

It requires interpretation by trained cancer genetics professionals.

Wow.

So we covered a massive amount of ground today.

We moved from understanding the baseline population statistics to mapping the exact genetic distance on a three generation pedigree using the Ontario tool.

We navigated the loopholes of Gina during pre -test counseling, decoded the psychology of the four test outcomes, including the survivor guilt of a true negative, and mapped out the heavy life -altering decisions surrounding MRIs and surgically induced menopause.

You've really seen how history -taking directly supports focused clinical interpretation and how that interpretation forces a management decision.

If we connect this to the bigger picture, it's about translating data into action.

Absolutely.

And I want to leave you with a provocative thought about where this is all heading.

We spent this entire deep dive talking about how to manage these mutations through intense surveillance and radical surgery.

But what happens in a decade when we don't just screen for the broken BRCA inspector, but we use CRISPR gene editing to permanently fix the mutation in a human embryo?

That's the real frontier.

Yeah.

You won't just be advising a 35 -year -old on removing her ovaries.

You might be counseling a 25 -year -old on whether to permanently edit the germline of her future children, eradicating the genetic ghost from her family tray forever.

The ethical and clinical weight of that decision will be entirely in your hands.

The science will keep evolving.

There's no doubt about that.

But your ability to translate that science into compassionate, evidence -based patient care will always be the core of what you do.

Well said.

Thank you for studying with us today.

Keep asking the hard questions.

And a warm thank you and sign off from the Last Minute Lecture team.

We will catch you on the next deep dive.